Makino S, Kashii A, Kanazawa K, Tsuchida Y
Department of Surgery, Jichi Medical School, Tochigi, Japan.
J Pediatr Surg. 1993 Apr;28(4):612-6. doi: 10.1016/0022-3468(93)90671-7.
A human neuroblastoma xenograft, designated TNB9, was used in this experiment. This xenograft is known to have a homogeneously staining region (HSR) on chromosome 20 and to exhibit 60- to 100-fold amplification of clones 8, G21 and N-myc, and showed a rapid tumor weight doubling time of 5.9 days; it represents one of the most malignant strains of human neuroblastoma. The effects of nine different chemotherapeutic agents on this xenograft were studied according to the standard Battelle Columbus Laboratories protocol, and the in vivo chemotherapeutic sensitivity assessment disclosed that Mitomycin C, Ifosfamide, and Carboplatin were highly effective against it, while VP-16, NK-171, 5-Fluorouracil, and THP-Adriamycin were ineffective. Cytogenetic and molecular-cytogenetic analyses suggest that the present data may accurately predict the clinical results with these chemotherapeutic agents in treating patients in advanced stages, as did those from our previous studies. Inclusion of Mitomycin C, Ifosfamide, and/or Carboplatin into a new chemotherapeutic protocol may be recommended.
本实验使用了一种名为TNB9的人神经母细胞瘤异种移植瘤。已知该异种移植瘤在20号染色体上有一个均匀染色区（HSR），并表现出克隆8、G21和N - myc基因60至100倍的扩增，且肿瘤重量倍增时间为5.9天，增长迅速；它代表了人类神经母细胞瘤中最恶性的菌株之一。根据巴特尔哥伦布实验室的标准方案，研究了九种不同化疗药物对该异种移植瘤的影响，体内化疗敏感性评估显示丝裂霉素C、异环磷酰胺和卡铂对其高度有效，而依托泊苷、NK - 171、5 - 氟尿嘧啶和吡柔比星则无效。细胞遗传学和分子细胞遗传学分析表明，目前的数据可能像我们之前研究的数据一样，准确预测这些化疗药物在治疗晚期患者时的临床结果。建议在新的化疗方案中加入丝裂霉素C、异环磷酰胺和/或卡铂。
